Clinical Trials
55 trialsNatural History Study of Patients With Neurofibromatosis Type I
National Institutes of Health Clinical Center (CC)
Natural History and Biology of Skin Neurofibromas in Neurofibromatosis Type 1
National Institutes of Health Clinical Center (CC)
Gait in Young Children With NF1
NYU Langone Health
Study of Disease Severity in Adults With Neurofibromatosis Type 1 (NF1)
National Institutes of Health Clinical Center (CC)
Real-World Treatment Study of Koselugo (Selumetinib)
AstraZeneca
Development of Patient-Reported Outcome Measures Assessing Tumor Visibility and Appearance Concerns in Neurofibromatosis Type 1: A Qualitative Study
National Institutes of Health Clinical Center (CC)
Development and Validation of Patient Reported Outcome (PRO) Measures for Individuals With Neurofibromatosis 1 (NF1) and Plexiform Neurofibromas (pNFs)
National Institutes of Health Clinical Center (CC)
SJFAMILY
St. Jude Children's Research Hospital
PRECIOUS Egypt
AstraZeneca
PASS of Paediatric Patients Initiating Selumetinib
AstraZeneca
FARD
Institut National de la Santé Et de la Recherche Médicale, France
Multi-parametric Biomarker Development to Predict Malignant Conversion in Patients With Neurofibromatosis Type 1
Johns Hopkins University
NF1-TED
Boston Children's Hospital
Precision Medicine for Neurocutaneous Syndromes in Western China
West China Hospital
RASopathy Biorepository
Children's Hospital Medical Center, Cincinnati
Evaluating Genetic Modifiers of Cutaneous Neurofibromas in Adults With Neurofibromatosis Type 1
Stanford University
cNF Natural Hx
Johns Hopkins University
Surveillance for Malignant Transformation of Neurofibromatosis Type 1 (NF1) Related Peripheral Nerve Sheath Tumors (PNST)
National Institutes of Health Clinical Center (CC)
NEF-1
Assistance Publique - Hôpitaux de Paris
Developing Biomarkers of Plexiform Tumor Burden in Patients With Neurofibromatosis-Type 1
Ann & Robert H Lurie Children's Hospital of Chicago
Targeting the Mechanisms Underlying Cutaneous Neurofibroma Formation in NF1: A Clinical Translational Approach.
Corewell Health West
Evaluating Mitochondrial Dysfunction in Patients With Neurofibromatosis Type 1
University of Arkansas
US Selumetinib Registry
Alexion Pharmaceuticals, Inc.
MicroRNAs in Patients With Neurofibromatosis Type 1
Ann & Robert H Lurie Children's Hospital of Chicago
NF1
University Hospital, Strasbourg, France
Incidence of Malignant Peripheral Nerve Sheath Tumor (MPNST) Development in Participants With Neurofibromatosis Type 1 (NF1) Receiving and Not Receiving Medical Therapies Directed at Plexiform Neurofibromas (PN)
National Institutes of Health Clinical Center (CC)
Analysis of Data Collected From Individuals Administered Neurobehavioral Assessments
National Institutes of Health Clinical Center (CC)
Genetic Bases of Neuroendocrine Neoplasms in Mexican Patients
Universidad Nacional Autonoma de Mexico
A Retrospective Study on Epidemiological Characteristics of Chinese NF1 Patients in Real World (PROMISE)
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Systematically Assessing Changes in Plexiform Neurofibroma Related Disfigurement From Photographs of Subjects With Neurofibromatosis Type 1 on a Phase 2 Clinical Trial
National Institutes of Health Clinical Center (CC)
Stem Cells in NF1 Patients With Tumors of the Central Nervous System
Children's National Research Institute
Neurofibromatosis (NF) Registry Portal
The Children's Tumor Foundation
Reliability of Functional Outcome Measures in Neurofibromatosis 1: Test- Retest
Guy's and St Thomas' NHS Foundation Trust
Frameshift Peptides of Children With NF1
Children's National Research Institute
Eligibility Screening for a NCI Pediatric Oncology Branch Research Study
National Institutes of Health Clinical Center (CC)
Adaptation and Quality of Life Among Adults With Neurofibromatosis Type I
National Institutes of Health Clinical Center (CC)
Genetic Evaluation of NF1 and Scoliosis Patients
University of Minnesota
NF1TD
Shriners Hospitals for Children
Multi-center Project: Spinal Abnormalities in Neurofibromatosis Type1 (NF1) Patients
Shriners Hospitals for Children
Internet Support Group for Parents of a Child With Neurofibromatosis Type 1
National Institutes of Health Clinical Center (CC)
CMMRD in NF1
Medical University Innsbruck
Spine
University of Utah
NF1
University Hospital, Brest
NPRI
Washington University School of Medicine
Neurofibromatosis Type 1 Brain Tumor Genetic Risk
Washington University School of Medicine
Analysis of Plasma for Diagnosis and Follow-up of Neurofibromatosis Type 1
Turku University Hospital
Reliability of Functional Outcome Measures in Neurofibromatosis 1
Guy's and St Thomas' NHS Foundation Trust
Subtle Myocardial Deformation Abnormalities in Asymptomatic Nf-1 Patients
Tel-Aviv Sourasky Medical Center
COVANTT
Erasmus Medical Center
Ophthalmological Screening and Follow-up of Optic Pathway Gliomas in Children With Neurofibromatosis Type 1.
Universitaire Ziekenhuizen KU Leuven